InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy

French biotech InnaVirVax has rallied investors to pump $4.9 million into its coffers via a Series B round of financing. The company will use the proceeds to begin trials of its drug VAC-3S, which is intended to boost the immune systems of HIV-infected patients. Investors in the round included lead backers Fa Dièse and Fonds Régional de Co-Investissement d'Ile-de-France, along with contributions from CapDecisif 2 and G1J Ile-de-France. "Thanks to them, we will be able to carry out the first in man study with our VAC-3S immunotherapy, for which we received the authorization from the AFSSAPS (the French Drug Agency)," InnaVirVax CEO Joël Crouzet explained in a statement. "Based on a cutting edge discovery aiming at protecting the immune system in HIV-infected patients, this candidate immunotherapy represents a fantastic challenge and we think that it should be an effective therapeutic answer for patients at different stages of the disease." Release

Suggested Articles

A who’s who of Big Pharmas, including Pfizer, Johnson & Johnson and Merck, have banded together to bolster the development of new antibiotics.

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.